ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Sep 2023
Last Updated on 01 Sep 2023
A- A+
Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee is unable to make a recommendation on pralsetinib for inclusion on the MOH List of Subsidised Drugs because the company has withdrawn its application from the company-led submission process due to the decision to end its global collaboration agreement to develop and commercialise pralsetinib. This submission was for treating rearranged during transfection (RET) fusion-positive, locally advanced or metastatic non-small-cell lung cancer.


Pralsetinib for treating RET fusion-positive locally advanced or metastatic non-small-cell lung cancer (Published 1 Sep 23)